Clever Culture Systems Reports Growth Momentum
Key points
- 3 APAS® sales completed in Q1 FY27
- New Top-20 pharmaceutical company to start APAS® evaluation
- PSC Biotech partnership extends market reach
- Expected H1 FY27 sales to reach 8 units
Full summary
Clever Culture Systems Ltd (ASX: CC5) reports continued commercial momentum for APAS® Independence, with completed sales, progressing customer evaluations, and an advancing sales pipeline. Highlights include 3 APAS® sales completed and invoiced in Q1 FY27, a new Top-20 global pharmaceutical company expected to commence a paid evaluation, and a partnership with PSC Biotech adding an additional commercial sales channel. The company expects H1 FY27 sales and new evaluations to reach 8 units, matching full-year FY26.
Outlook
The continued commercial momentum and recently announced PSC Biotech partnership underpin both the company's FY27 objectives and longer-term growth ambitions.
Summary generated by a large language model. Please interpret with care.